{
  "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "docSlug": "9e6f9592721adb102aeba3d640e068ca",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 41,
  "pageCount": 64,
  "prevPage": 40,
  "nextPage": 42,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Uses icon-based visualization to represent market expansion.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/41",
  "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "deckJsonHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd.json",
  "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-41",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.87,
        "y": 0.03
      },
      "kind": "image",
      "text": "IMMIX BIOPHARMA",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "914e1087-1ae3-4963-8584-353434ecd19d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.1,
        "x": 0.02,
        "y": 0.72
      },
      "kind": "list",
      "text": "NXC-201 Treatment Options",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7163a1c7-ed03-491d-b02a-d9ad05fd3ae4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.1,
        "x": 0.02,
        "y": 0.32
      },
      "kind": "list",
      "text": "Today – CAR-T Treatment Options",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4ae55d9-9bdb-452c-a710-2e527aafcd94",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.2,
        "x": 0.115,
        "y": 0.34
      },
      "kind": "paragraph",
      "text": "Today: CAR-T is accessible at only 5% of US hospitals, mostly academic research centers in major cities",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1d8c8c7b-50e6-439d-b277-15d936800f6a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.4,
        "x": 0.145,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "Future: NXC-201 potentially accessible at many more US hospitals, academic research centers in cities + regional medical centers and clinics",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f341afe-d3f6-406b-8967-18fb3a0a0321",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.98,
        "x": 0.01,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Sharma A, et al, Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients. Transplant Cell Ther. 2023 Feb;29(2):108.e1-108.e7. doi: 10.1016/j.jtct.2022.11.004. Epub 2022 Nov 9. PMID: 36371048. George Washington University “The Differences Between Academic and Community Medical Centers”",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c37ea5da-99b3-4340-928a-aa6e6cdf1384",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Outpatient Access To NXC-201 Potentially Increases CAR-T Addressable Market by 10-20x",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8280bd1d-a5be-469e-b0b8-3b2aa28e00ec",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 64,
      "from": 37,
      "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}